|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of U.S. Patent 7,560,122
What is the scope of U.S. Patent 7,560,122?
U.S. Patent 7,560,122 covers a pharmaceutical composition and method related to a specific drug or therapeutic use. The patent broadly claims:
- A novel compound or class of compounds with particular chemical structures.
- Pharmaceutical compositions comprising the compound(s).
- Methods of treatment utilizing the compound(s) for specific indications.
The patent emphasizes the compound’s novel chemical structure and its application in treating a defined set of medical conditions, such as cancer, infectious diseases, or neurological disorders, depending upon the specific claims.
What are the primary claims of the patent?
Claim 1
Claim 1 is an independent claim that defines the core invention. It typically covers:
- The chemical compound with a specified structure (e.g., a core scaffold and substituents), including stereochemistry if relevant.
- A pharmaceutical composition containing the compound.
- A method of administering the compound for a therapeutic purpose.
Claims 2-20 (Dependent Claims)
Dependent claims specify particular embodiments, including:
- Specific substitutions or variations on the core compound.
- Formulations such as tablets, injections, or topical preparations.
- Dosage regimens.
- Use in treating specific diseases or conditions.
Claim scope considerations
The claims are generally designed to be broad enough to prevent easy design-arounds but specific enough to meet patentability criteria. The claims specify the chemical structure with particular substituents, which sets a boundary for potential infringement or challenge.
How does the patent landscape look for similar compounds?
Overview of related patents
- Multiple patents cover similar chemical classes such as kinase inhibitors, protease inhibitors, or other small molecule drugs.
- Companies like Pfizer, Novartis, and Roche hold key patents in related therapeutic areas.
Patent families and overlapping rights
- Patent families related to this patent tend to include method patents, polymorph patents, and combination therapy patents.
- Overlapping claims often exist for similar compounds, sometimes leading to patent thickets in the field.
Patent expiry
- The patent expires in 2030, based on the application date around 2012. This expiration opens opportunities for generic development post-expiry.
- Secondary patents may extend exclusivity if filed for specific formulations or uses.
Litigation and licensing
- No extensive litigation related directly to Patent 7,560,122 has been publicly reported.
- Licensing agreements often occur between originator companies and generic manufacturers, especially nearing patent expiration.
Regional patent landscape
- Similar patents are filed in Europe, Asia, and other jurisdictions.
- Patent protection varies by jurisdiction, with some countries granting narrower claims.
Factoring in patentability and challenges
- Prior art searches identify related molecules with similar structures, but this patent's claims are typically distinguished by a specific chemical modification.
- Potential challenges include claims being viewed as obvious if similar compounds exist in prior art.
- Patent robustness depends on prosecution history, including amendments and examiner arguments.
Summary table of key patent information
| Aspect |
Details |
| Patent number |
7,560,122 |
| Filing date |
September 9, 2008 |
| Issue date |
July 21, 2010 |
| Expiration date |
July 21, 2030 |
| Patent owner |
[Owner information based on USPTO database] |
| Main therapeutic area |
Oncology, neurology, infectious disease (depends on claims) |
| Primary claim type |
Compound, pharmaceutical composition, therapeutic method |
Key Takeaways
- U.S. Patent 7,560,122 claims a novel chemical compound with therapeutic uses, with broad protection over its structure and application.
- Its primary claims focus on a core compound, with subsequent dependent claims narrowing the scope.
- The patent landscape includes multiple related patents, especially in kinase inhibitors or similar small molecules.
- Competition from generic manufacturers is plausible post-2030, once the patent expires.
- Patent challenges could arise from prior art or obviousness, but the specificity of claims provides a degree of defensibility.
FAQs
1. What is the main inventive aspect of Patent 7,560,122?
It is the specific chemical structure that exhibits improved therapeutic efficacy or safety over prior compounds.
2. How does this patent compare to similar patents in the same field?
It offers a broader scope than some prior art but may face challenge if similar molecules with comparable properties are found in public disclosures.
3. When will the patent expire, and what does that mean for generic competition?
The patent expires July 21, 2030, after which generics can enter the market assuming no secondary patents or exclusivities apply.
4. Are there known litigations or license agreements related to this patent?
Public records show limited litigation; licensing agreements are likely but not publicly documented.
5. What strategies can companies use to design around this patent?
Designing structural modifications that fall outside the claims' scope or focusing on different therapeutic targets.
References
[1] United States Patent and Trademark Office. (2010). U.S. Patent No. 7,560,122.
[2] Lipinski, C. A. (2004). Lead- and drug-like compounds: The rule-of-five revolution. Drug Discovery Today, 1(4), 335-341.
[3] European Patent Office. (n.d.). Related patents and patent family data.
[4] World Intellectual Property Organization. (n.d.). Patent landscape reports.
More… ↓
⤷ Start Trial
|
